Last updated: September 5, 2026

Technetium Tc-99m mebrofenin is a mature hepatobiliary diagnostic radiopharmaceutical sold primarily in the United States as Choletec, a kit used to prepare technetium Tc-99m mebrofenin injection. Bracco Diagnostics is the principal commercial sponsor identified in FDA labeling. The product has no meaningful remaining composition-of-matter exclusivity, no biosimilar pathway, and limited patent-based protection. Its commercial value depends on recurring hepatobiliary imaging demand, hospital and radiopharmacy purchasing, manufacturing reliability, and access to technetium-99m rather than on high prescription pricing or patent exclusivity.[1]

Public sources do not disclose standalone revenue for technetium Tc-99m mebrofenin. Its financial trajectory is therefore best assessed through procedure demand, radiopharmaceutical supply conditions, competitive availability, and the economics of kit-based nuclear medicine products.

What is technetium Tc-99m mebrofenin used for?

Technetium Tc-99m mebrofenin is used for hepatobiliary imaging, including evaluation of the liver, gallbladder, bile ducts, and cystic duct. The principal clinical procedure is hepatobiliary iminodiacetic acid imaging, commonly called HIDA scanning or cholescintigraphy.

The FDA-approved product is supplied as a nonradioactive kit. A radiopharmacy adds sodium pertechnetate Tc-99m to the vial before administration. The resulting radiopharmaceutical is injected intravenously and imaged with a gamma camera.[1]

Primary clinical applications

The product is used in:

Suspected acute cholecystitis
Cystic duct obstruction
Gallbladder function assessment
Biliary obstruction
Bile leaks
Postoperative hepatobiliary evaluation
Selected pediatric hepatobiliary studies

The demand base is tied to emergency-department, inpatient, outpatient, and pediatric imaging volumes. Utilization is influenced by ultrasound and magnetic resonance imaging availability, but those modalities do not fully replace functional biliary imaging.

What is the FDA regulatory status of technetium Tc-99m mebrofenin?

The FDA approved Choletec under NDA 018691. The product is a diagnostic radiopharmaceutical kit rather than a conventional mass-market prescription medicine. Its commercial form is prepared at or near the point of care because technetium-99m has a physical half-life of about six hours.[1,2]

Regulatory attribute	Status
Active diagnostic agent	Technetium Tc-99m mebrofenin
Nonradioactive kit component	Mebrofenin vial and formulation excipients
Primary brand	Choletec
Principal sponsor identified in labeling	Bracco Diagnostics Inc.
FDA pathway	New drug application for a diagnostic radiopharmaceutical
Primary use	Hepatobiliary imaging
Administration	Intravenous after radiolabeling
Biosimilar pathway	Not applicable
Generic substitution	Limited by radiopharmacy preparation, supply, and institutional purchasing

Unlike biologics, technetium Tc-99m mebrofenin does not face biosimilar competition. Competition occurs through other hepatobiliary radiopharmaceuticals, alternative imaging procedures, and substitute suppliers of kits or prepared doses.

What patents protect technetium Tc-99m mebrofenin?

The commercial patent estate is weak relative to newer pharmaceutical products. The original Choletec approval dates to the 1980s, placing any original product, formulation, or use patents well beyond their ordinary 20-year patent term. FDA product information does not identify an active patent-based exclusivity period comparable to that of a recently approved drug.[1,3]

Patent and exclusivity position

Protection category	Commercial assessment
Composition-of-matter patent	No meaningful active protection expected for the mature mebrofenin molecule
Original product patent	Expired based on the age of the product
Formulation patent	No publicly prominent current formulation barrier identified
Method-of-use patent	No publicly prominent current method-of-use barrier identified
Regulatory exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	No current commercial relevance identified
Biosimilar exclusivity	Not applicable
Orange Book value	Limited; the product is mature and its commercial protection is not patent-led

What is the Orange Book status of Choletec?

The Orange Book is less commercially important for Choletec than for a conventional oral or injectable small-molecule product. The product is a radiopharmaceutical kit with long-established clinical use and limited patent protection. No active Orange Book exclusivity is the principal barrier to competition. Market access depends more heavily on FDA manufacturing compliance, radiopharmaceutical distribution, technetium supply, and hospital contracting.[3]

When does technetium Tc-99m mebrofenin lose exclusivity?

The product effectively lost meaningful exclusivity decades ago. The FDA approval occurred in the 1980s, and any ordinary small-molecule patent protection associated with the original product would have expired long before the current market period.

The practical exclusivity timeline is:

Period	Commercial significance
1980s	FDA approval and initial branded-market development
1990s-2000s	Decline in patent-based protection as ordinary terms expired
2010s	Mature diagnostic radiopharmaceutical market
Current market	Competition based on supply, quality, price, and radiopharmacy access

There is no apparent near-term patent cliff comparable to those affecting high-revenue specialty medicines. The relevant commercial question is whether a supplier can maintain dependable kit production and distribution.

What formulations are protected by technetium Tc-99m mebrofenin patents?

The product is supplied as a lyophilized kit for radiolabeling with sodium pertechnetate Tc-99m. The formulation and preparation process are technically important but do not appear to create a durable patent moat today.

The principal manufacturing requirements include:

Production of a sterile, stable nonradioactive kit.
Compatibility with Tc-99m pertechnetate.
Consistent radiochemical purity after labeling.
Validated shelf life and storage conditions.
Batch release testing suitable for short-lived radiopharmaceutical use.
Distribution to radiopharmacies within operational time limits.

These requirements create regulatory and manufacturing barriers even when patents are absent. A competitor must demonstrate reproducible labeling performance, sterility, identity, strength, purity, and stability under FDA standards.[1,4]

How does technetium Tc-99m mebrofenin compare with competing hepatobiliary agents?

Mebrofenin competes with other iminodiacetic acid derivatives, including disofenin and related hepatobiliary imaging agents. It also competes indirectly with ultrasound, computed tomography, magnetic resonance cholangiopancreatography, and endoscopic procedures.

Factor	Tc-99m mebrofenin	Other HIDA agents	Ultrasound/MR alternatives
Primary use	Functional hepatobiliary imaging	Functional hepatobiliary imaging	Structural imaging
Gallbladder assessment	Strong clinical role	Comparable, depending on agent	Ultrasound often first line
Biliary obstruction	Useful	Useful	MRCP may provide anatomical detail
Supply model	Kit plus Tc-99m	Similar radiopharmacy model	Conventional imaging infrastructure
Patent strength	Low	Generally mature	Device and software patents vary
Revenue model	Per-procedure radiopharmaceutical	Per-procedure radiopharmaceutical	Imaging facility and professional fees
Key competitive factor	Availability and workflow reliability	Availability, price, local preference	Modality access and clinical protocol

Mebrofenin can retain demand because HIDA imaging provides functional information that structural imaging does not always replicate. The agent's commercial position is strongest in institutions with established nuclear medicine departments and dependable Tc-99m access.

What market dynamics affect technetium Tc-99m mebrofenin revenue?

The market has several structural characteristics.

Technetium-99m supply

Technetium-99m is generated from molybdenum-99 and is commonly supplied through nuclear medicine generators. Any interruption in Mo-99 production, generator distribution, transportation, or radiopharmacy operations can reduce completed procedures. The short half-life limits inventory and increases the importance of local supply coordination.[2,5]

Radiopharmacy economics

Radiopharmacies typically prepare doses close to the time of administration. This reduces conventional wholesaler inventory but increases operational sensitivity to:

Generator delivery schedules
Hospital procedure cancellations
Radiochemical quality control
Transportation timing
Staffing and licensure
Waste from unused short-lived doses

A kit supplier can lose orders even when underlying diagnostic demand remains stable if a radiopharmacy lacks Tc-99m or cannot complete same-day preparation.

Hospital purchasing

Purchasing decisions are typically influenced by price, contract terms, availability, validated preparation procedures, and clinical familiarity. Because mebrofenin is a mature product, price increases are constrained by the availability of alternative diagnostic agents and institutional procurement pressure.

Procedure volumes

Demand generally follows emergency and inpatient evaluation of suspected biliary disease, surgical complications, and pediatric hepatobiliary disorders. Aging populations and high rates of gallbladder disease support a recurring clinical base, but utilization is moderated by ultrasound-first diagnostic pathways and local imaging protocols.

What is the financial trajectory of technetium Tc-99m mebrofenin?

No public source reviewed reports standalone global or U.S. revenue, unit volume, gross margin, or operating income for technetium Tc-99m mebrofenin. Bracco reports at a corporate level rather than providing a separate financial line for Choletec.[6]

The likely financial profile is that of a mature, recurring, low-growth diagnostic product:

Financial driver	Expected effect
Patent expiration	Limits premium pricing and supports competitive pressure
Recurring HIDA procedures	Provides stable baseline demand
Tc-99m availability	Creates short-term revenue volatility
Manufacturing compliance	Raises fixed operating requirements
Hospital contracting	Compresses net pricing
Product shortages	Can shift demand to substitute agents
Low inventory life	Increases waste and fulfillment risk
New clinical indications	Limited upside without new evidence or labeling

Revenue is likely more stable than that of a drug dependent on new patient starts, but less scalable than a conventional pharmaceutical because every dose depends on procedure scheduling and isotope logistics. Margin performance depends on manufacturing scale, fill-finish efficiency, quality-control costs, distribution density, and the ability to avoid discarded prepared doses.

Which companies are challenging technetium Tc-99m mebrofenin?

Competitive pressure comes from three groups:

Suppliers of other HIDA radiopharmaceutical kits.
Radiopharmacies that prepare or distribute doses through institutional networks.
Diagnostic alternatives, particularly ultrasound and MRCP.

No prominent Paragraph IV litigation pattern is associated with technetium Tc-99m mebrofenin in the public record reviewed. The product's age and limited patent estate reduce the commercial rationale for a patent challenge. A new entrant would more likely pursue FDA approval or an abbreviated pathway, where available, and compete on supply reliability, price, or contracting.

What patent litigation and settlement agreements affect the product?

No major active patent litigation or publicly prominent settlement agreement is identified for Choletec in the cited FDA and company materials. The absence of litigation is consistent with a mature diagnostic agent whose key commercial barriers are operational rather than patent-based.

A market entrant would face greater risk from regulatory deficiencies, sterility failures, inconsistent radiochemical purity, or supply-chain interruptions than from a blocking patent injunction.

What generic launch risks exist for technetium Tc-99m mebrofenin?

A new entrant could theoretically launch a competing mebrofenin kit without confronting significant patent exclusivity. The principal risks would include:

FDA approval and facility inspection
Demonstration of pharmaceutical equivalence or comparable performance
Validated radiolabeling procedures
Sterility and endotoxin control
Reliable access to vial components and excipients
Radiopharmacy adoption
Hospital formulary and purchasing approval
Limited market size relative to development and manufacturing costs
Competition from established HIDA products

The market may be too small to support multiple large suppliers at attractive margins. That condition can discourage entry even where patent protection is weak.

How strong is the patent estate for technetium Tc-99m mebrofenin?

The patent estate is weak. The product has no evident active exclusivity that would materially prevent competition. Its defensibility comes from regulatory know-how, manufacturing validation, customer relationships, distribution, and supply reliability.

For investors or licensing parties, the asset is better characterized as a mature commercial radiopharmaceutical franchise than as a patent-protected growth product.

Key Takeaways

Technetium Tc-99m mebrofenin is a mature hepatobiliary diagnostic radiopharmaceutical marketed primarily as Choletec.
Bracco Diagnostics is the principal sponsor identified in FDA labeling.
The product's original patent and regulatory exclusivity periods are long expired.
No biosimilar pathway applies.
No major active Orange Book, Paragraph IV, patent litigation, or settlement issue is central to the product's market position.
Revenue is recurring but likely modest and is not publicly disclosed as a standalone figure.
The strongest commercial barriers are FDA-compliant manufacturing, Tc-99m access, radiopharmacy execution, and hospital contracting.
Financial performance is likely stable to low-growth, with volatility caused by isotope shortages, procedure volumes, and supply interruptions.
Competitive risk comes from alternative HIDA agents and structural imaging rather than from a single imminent generic patent launch.

FAQs

Is technetium Tc-99m mebrofenin a generic drug?

It is a mature diagnostic radiopharmaceutical kit with limited patent protection. Commercial competition can occur through alternative approved products and suppliers, although radiopharmacy preparation and hospital procurement make substitution more complex than for a standard tablet.

Does technetium Tc-99m mebrofenin have biosimilars?

No. Biosimilars apply to biological products. Technetium Tc-99m mebrofenin is a small-molecule radiopharmaceutical.

Who manufactures Choletec?

Bracco Diagnostics is identified as the manufacturer or sponsor in FDA product information for Choletec.[1]

What is the main supply risk for technetium Tc-99m mebrofenin?

The principal risk is access to Tc-99m generated from Mo-99, combined with radiopharmacy timing, transportation, quality-control, and procedure scheduling requirements.

Is technetium Tc-99m mebrofenin a high-growth pharmaceutical product?

No. It is best classified as a mature, recurring diagnostic product. Growth is constrained by established clinical use, limited patent protection, modest procedure expansion, and competition from ultrasound and other imaging modalities.

References

U.S. Food and Drug Administration. (n.d.). Choletec: Technetium Tc 99m mebrofenin kit prescribing information. FDA Drugs@FDA.
National Cancer Institute. (n.d.). Technetium Tc-99m. NCI Drug Dictionary.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2019). PET drugs: Current good manufacturing practice and quality control guidance. FDA.
International Atomic Energy Agency. (n.d.). Molybdenum-99/technetium-99m supply and nuclear medicine resources. IAEA.
Bracco S.p.A. (n.d.). Annual and corporate information. Bracco.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	TECHNETIUM TC-99M MEBROFENIN at DailyMed

Sponsor	Phase
UNC Lineberger Comprehensive Cancer Center	Phase 1
National Cancer Institute (NCI)	Phase 1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	TECHNETIUM TC-99M MEBROFENIN	technetium tc-99m mebrofenin kit	INJECTABLE;INJECTION	078242-001	Jan 29, 2008	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

TECHNETIUM TC-99M MEBROFENIN Drug Patent Profile

When do Technetium Tc-99m Mebrofenin patents expire, and when can generic versions of Technetium Tc-99m Mebrofenin launch?

AI Deep Research

Questions you can ask:

Summary for TECHNETIUM TC-99M MEBROFENIN

Recent Clinical Trials for TECHNETIUM TC-99M MEBROFENIN

US Patents and Regulatory Information for TECHNETIUM TC-99M MEBROFENIN

Technetium Tc-99m Mebrofenin Market Dynamics, Patent Position and Financial Trajectory